| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024969042 |
| P356 | DOI | 10.1038/376683A0 |
| P698 | PubMed publication ID | 7651517 |
| P5875 | ResearchGate publication ID | 15546674 |
| P2093 | author name string | Bennett PB | |
| George AL Jr | |||
| Makita N | |||
| Yazawa K | |||
| P2860 | cites work | Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches | Q22337395 |
| A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel | Q24316252 | ||
| A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome | Q24316980 | ||
| SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome | Q24317024 | ||
| Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel | Q24563388 | ||
| The long QT syndrome. Prospective longitudinal study of 328 families | Q33156679 | ||
| Gating of cardiac Na+ channels in excised membrane patches after modification by alpha-chymotrypsin | Q34018174 | ||
| Patch clamp measurements on Xenopus laevis oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels | Q34390940 | ||
| Pathogenesis and therapy of the idiopathic long QT syndrome | Q35252711 | ||
| Molecular kinetics of voltage-dependent Na+ channels | Q36431859 | ||
| Amino acid residues required for fast Na(+)-channel inactivation: charge neutralizations and deletions in the III-IV linker | Q37301144 | ||
| A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation | Q37301303 | ||
| Two modes of gating during late Na+ channel currents in frog sartorius muscle | Q38160222 | ||
| Mechanisms and control of repolarization | Q40807704 | ||
| Modal gating behavior of cardiac sodium channels in cell-free membrane patches | Q41184826 | ||
| A cellular basis for the primary long Q-T syndromes | Q44484819 | ||
| Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes | Q46510208 | ||
| Modal gating of Na+ channels as a mechanism of persistent Na+ current in pyramidal neurons from rat and cat sensorimotor cortex. | Q48341696 | ||
| Assignment of the human heart tetrodotoxin-resistant voltage-gated Na+ channel alpha-subunit gene (SCN5A) to band 3p21. | Q51614266 | ||
| Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity | Q58011214 | ||
| Structural parts involved in activation and inactivation of the sodium channel | Q59072056 | ||
| Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene | Q68298471 | ||
| Inactivation-resistant channels underlying the persistent sodium current in rat ventricular myocytes | Q72055880 | ||
| P433 | issue | 6542 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart arrhythmia | Q189331 |
| P304 | page(s) | 683-685 | |
| P577 | publication date | 1995-08-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Molecular mechanism for an inherited cardiac arrhythmia | |
| P478 | volume | 376 |
| Q51255895 | 16-Channel Organic Electrochemical Transistor Array for In Vitro Conduction Mapping of Cardiac Action Potential. |
| Q38101328 | A Memory Molecule, Ca(2+)/Calmodulin-Dependent Protein Kinase II and Redox Stress; Key Factors for Arrhythmias in a Diseased Heart |
| Q57816587 | A New Cardiac Channelopathy: From Clinical Phenotypes to Molecular Mechanisms Associated With Na1.5 Gating Pores |
| Q33162301 | A case of Long QT syndrome type 3 aggravated by beta-blockers and alleviated by mexiletine: the role of epinephrine provocation test |
| Q33159495 | A common SCN5A polymorphism modulates the biophysical defects of SCN5A mutations |
| Q34331339 | A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y |
| Q28138550 | A common polymorphism associated with antibiotic-induced cardiac arrhythmia |
| Q49851013 | A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality |
| Q80152306 | A composite model for HERG blockade |
| Q51695191 | A computational model of Purkinje fibre single cell electrophysiology: implications for the long QT syndrome. |
| Q33751744 | A computational model predicts adjunctive pharmacotherapy for cardiac safety via selective inhibition of the late cardiac Na current. |
| Q30882091 | A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current |
| Q33732880 | A contemporary review on the genetic basis of atrial fibrillation |
| Q48944651 | A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome |
| Q74315934 | A defect in skeletal muscle sodium channel deactivation exacerbates hyperexcitability in human paramyotonia congenita |
| Q93257620 | A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant |
| Q49049294 | A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities |
| Q49958380 | A hERG mutation E1039X produced a synergistic lesion on IKs together with KCNQ1-R174C mutation in a LQTS family with three compound mutations |
| Q30493789 | A large family characterised by nocturnal sudden death |
| Q83227345 | A microtranslatome coordinately regulates sodium and potassium currents in the human heart |
| Q24626279 | A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction |
| Q40559348 | A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. |
| Q55670913 | A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome |
| Q33148068 | A novel SCN5A mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. |
| Q28471659 | A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response |
| Q24318498 | A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome |
| Q41382464 | A practical approach to torsade de pointes |
| Q34432684 | A revised view of cardiac sodium channel "blockade" in the long-QT syndrome |
| Q28203120 | A sodium-channel mutation causes isolated cardiac conduction disease |
| Q35014380 | A surface plasmon resonance approach to monitor toxin interactions with an isolated voltage-gated sodium channel paddle motif. |
| Q28587278 | A β(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice |
| Q39320581 | About half of the late sodium current in cardiac myocytes from dog ventricle is due to non-cardiac-type Na(+) channels |
| Q43726773 | Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. |
| Q64074201 | Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes |
| Q34173006 | Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study |
| Q33608238 | Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current |
| Q35679654 | Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes |
| Q77307443 | Altered atrial, atrioventricular, and ventricular conduction in patients with the long QT syndrome caused by the DeltaKPQ SCN5A sodium channel gene mutation |
| Q35900908 | Altered sinoatrial node function and intra-atrial conduction in murine gain-of-function Scn5a+/ΔKPQ hearts suggest an overlap syndrome. |
| Q34300731 | An EF-hand in the sodium channel couples intracellular calcium to cardiac excitability |
| Q46725746 | An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes |
| Q48496496 | Anemone toxin (ATX II)-induced increase in persistent sodium current: effects on the firing properties of rat neocortical pyramidal neurones |
| Q33628697 | Annotation of functional impact of voltage-gated sodium channel mutations |
| Q46574868 | Another calcium paradox in heart failure |
| Q33947683 | Antiarrhythmics--from cell to clinic: past, present, and future |
| Q91137880 | Arrhythmias precede cardiomyopathy and remodeling of Ca2+ handling proteins in a novel model of long QT syndrome |
| Q35553358 | Arrhythmogenic Biophysical Phenotype for SCN5A Mutation S1787N Depends upon Splice Variant Background and Intracellular Acidosis |
| Q90282403 | Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients |
| Q38111636 | Atrial selectivity of antiarrhythmic drugs |
| Q40833166 | Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes |
| Q41062827 | Bursting dynamics in the normal and failing hearts |
| Q35157593 | Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels |
| Q37899670 | CaMKII in the cardiovascular system: sensing redox states. |
| Q34574396 | Calcium-dependent regulation of the voltage-gated sodium channel hH1: intrinsic and extrinsic sensors use a common molecular switch |
| Q26999872 | Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias |
| Q47720327 | Cardiac Arrhythmias Related to Sodium Channel Dysfunction. |
| Q33583786 | Cardiac Na Channels: Structure to Function |
| Q35127761 | Cardiac Sodium Channel Diseases |
| Q34977809 | Cardiac ankyrins in health and disease |
| Q30426852 | Cardiac models in drug discovery and development: a review |
| Q38201409 | Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia |
| Q33964797 | Cardiac resynchronization therapy improves altered Na channel gating in canine model of dyssynchronous heart failure |
| Q26827778 | Cardiac sodium channel Nav1.5 mutations and cardiac arrhythmia |
| Q33906972 | Cardiac sodium channelopathies |
| Q38118751 | Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects |
| Q44813194 | Channel activation voltage alone is directly altered in an isoform-specific manner by Na(v1.4) and Na(v1.5) cytoplasmic linkers |
| Q28348752 | Channel cytoplasmic loops alter voltage-dependent sodium channel activation in an isoform-specific manner |
| Q26824051 | Channelopathies from mutations in the cardiac sodium channel protein complex |
| Q34051594 | Channelopathies: ion channel defects linked to heritable clinical disorders |
| Q43115368 | Characterization of N-terminally mutated cardiac Na(+) channels associated with long QT syndrome 3 and Brugada syndrome |
| Q90045249 | Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment |
| Q36689783 | Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome |
| Q35741443 | Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. |
| Q24302352 | Combination of cardiac conduction disease and long QT syndrome caused by mutation T1620K in the cardiac sodium channel |
| Q36015209 | Computational biology in the study of cardiac ion channels and cell electrophysiology. |
| Q26769921 | Conduction abnormalities and ventricular arrhythmogenesis: The roles of sodium channels and gap junctions |
| Q38663670 | Congenital Long QT syndrome and torsade de pointes. |
| Q33165312 | Congenital and drug-induced long-QT syndrome: an update |
| Q58010712 | Congenital long QT syndrome |
| Q28206505 | Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A) |
| Q30306576 | Contributions of charged residues in a cytoplasmic linking region to Na channel gating |
| Q38304968 | Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels |
| Q39356802 | Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes |
| Q24311774 | Correlations between clinical and physiological consequences of the novel mutation R878C in a highly conserved pore residue in the cardiac Na+ channel |
| Q36983062 | Deconstructing voltage sensor function and pharmacology in sodium channels |
| Q34977359 | Defective cardiac ion channels: from mutations to clinical syndromes |
| Q34095165 | Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins |
| Q38378616 | Deranged sodium to sudden death. |
| Q35798904 | Developmentally regulated SCN5A splice variant potentiates dysfunction of a novel mutation associated with severe fetal arrhythmia |
| Q37245096 | Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine |
| Q36295618 | Differential sialylation modulates voltage-gated Na+ channel gating throughout the developing myocardium |
| Q34017596 | Distinct local anesthetic affinities in Na+ channel subtypes |
| Q39661985 | Diversity in cardiac sodium channel disease phenotype in transgenic mice carrying a single SCN5A mutation. |
| Q33691511 | Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia |
| Q54243722 | Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. |
| Q43264586 | Effects of BDF 9198 on action potentials and ionic currents from guinea-pig isolated ventricular myocytes |
| Q49908057 | Effects of Benzothiazolamines on Voltage-Gated Sodium Channels. |
| Q35375182 | Effects of cardiac sympathetic innervation on regional wall motion abnormality in patients with long QT syndrome |
| Q79194716 | Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3 |
| Q39692743 | Electrophysiological characterization of a large set of novel variants in the SCN5A-gene: identification of novel LQTS3 and BrS mutations |
| Q37291478 | Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome |
| Q39144763 | Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets |
| Q92764271 | Enhanced closed-state inactivation of mutant cardiac sodium channels (SCN5A N1541D and R1632C) through different mechanisms |
| Q43142639 | Enhanced impact of SCN5A mutation associated with long QT syndrome in fetal splice isoform |
| Q40710544 | Enhancement of closed-state inactivation in long QT syndrome sodium channel mutation DeltaKPQ. |
| Q46507537 | Evidence for Non-neutral Evolution in a Sodium Channel Gene in African Weakly Electric Fish (Campylomormyrus, Mormyridae). |
| Q37231007 | F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models |
| Q36474150 | Familial Wolff-Parkinson-White Syndrome: a disease of glycogen storage or ion channel dysfunction? |
| Q37641802 | Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide |
| Q34035733 | From Fifth Business to Protagonist: the complex roles of ion channel anchors in cardiac arrhythmia |
| Q28143653 | From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels |
| Q28208131 | Functional characterization of the D188V mutation in neuronal voltage-gated sodium channel causing generalized epilepsy with febrile seizures plus (GEFS) |
| Q37240660 | Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect |
| Q24321619 | Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing |
| Q40043668 | Gating of the shaker potassium channel is modulated differentially by N-glycosylation and sialic acids |
| Q36681974 | Gender-based differences in cardiac diseases |
| Q58011012 | Gene-specific lethality of arrhythmic events in the long QT syndrome? A message from the International Registry |
| Q94539733 | Genetic Susceptibility for COVID-19-Associated Sudden Cardiac Death in African Americans |
| Q28265902 | Genetic basis and molecular mechanism for idiopathic ventricular fibrillation |
| Q34811193 | Genetic disorders of neuromuscular ion channels |
| Q33585556 | Genetics and Sinus Node Dysfunction |
| Q37729709 | Genetics and cardiac channelopathies. |
| Q26783570 | Genetics of inherited primary arrhythmia disorders |
| Q41746723 | Genetics, molecular mechanisms and management of long QT syndrome |
| Q38243946 | Genotype phenotype associations across the voltage-gated sodium channel family |
| Q37613089 | Genotype- and phenotype-guided management of congenital long QT syndrome |
| Q36412050 | Glutamine substitution at alanine1649 in the S4-S5 cytoplasmic loop of domain 4 removes the voltage sensitivity of fast inactivation in the human heart sodium channel |
| Q52544321 | Gradient of sodium current across the left ventricular wall of adult rat hearts. |
| Q39911980 | Hereditary Inclusion Body Myopathy (HIBM2) |
| Q27322725 | Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction |
| Q89787652 | Hypoxia Produces Pro-arrhythmic Late Sodium Current in Cardiac Myocytes by SUMOylation of NaV1.5 Channels |
| Q43559407 | Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome |
| Q34036797 | Impact of genetics on the clinical management of channelopathies |
| Q33789839 | Impact of recent molecular studies on evaluation of ventricular arrhythmias |
| Q40129475 | Inactivation of single cardiac Na+ channels in three different gating modes |
| Q36787316 | Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice |
| Q41970628 | Induction of high STAT1 expression in transgenic mice with LQTS and heart failure |
| Q33152183 | Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels |
| Q28236888 | Inherited conduction system abnormalities--one group of diseases, many genes |
| Q33905815 | Inherited disorders of voltage-gated sodium channels |
| Q33145216 | Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis |
| Q33672205 | Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders |
| Q40211980 | Inhibition of the cardiac Na⁺ channel α-subunit Nav1.5 by propofol and dexmedetomidine |
| Q36507053 | Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine |
| Q45825169 | Inhibitory effects of hesperetin on Nav1.5 channels stably expressed in HEK 293 cells and on the voltage-gated cardiac sodium current in human atrial myocytes |
| Q36670460 | Innovative approaches to anti-arrhythmic drug therapy. |
| Q34815219 | Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome |
| Q48534664 | Interaction between fast and ultra-slow inactivation in the voltage-gated sodium channel. Does the inactivation gate stabilize the channel structure? |
| Q26829681 | Ion Channels in the Heart |
| Q34311621 | Ion channel associated diseases: overview of molecular mechanisms |
| Q33603836 | Ion channel genes and human neurological disease: recent progress, prospects, and challenges. |
| Q60076592 | Ion channels lose the rhythm |
| Q35934207 | Ion channels: function unravelled by dysfunction |
| Q41415489 | Ion channels: structural basis for function and disease. |
| Q36355526 | Ion-selective optodes measure extracellular potassium flux in excitable cells |
| Q38856035 | Is There a Role for Genetics in the Prevention of Sudden Cardiac Death? |
| Q42390883 | Is long QT syndrome entering the era of molecular diagnosis? |
| Q51805811 | Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating. |
| Q36851172 | Knockin animal models of inherited arrhythmogenic diseases: what have we learned from them? |
| Q24313536 | KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias |
| Q48693041 | Late Sodium Channel Openings Underlying Epileptiform Activity Are Preferentially Diminished by the Anticonvulsant Phenytoin |
| Q27303632 | Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation |
| Q34433632 | Late cardiac sodium current can be assessed using automated patch-clamp |
| Q51517055 | Late sodium current dysregulation as a causal factor in arrhythmia. |
| Q36496273 | Late sodium current in failing heart: friend or foe? |
| Q36954069 | Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart |
| Q59087954 | Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia |
| Q37362215 | Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels |
| Q33145925 | Long QT Syndromes |
| Q73885519 | Long QT syndrome |
| Q34785746 | Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation |
| Q41867575 | Long QT syndrome: from channels to cardiac arrhythmias |
| Q35219529 | Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias |
| Q39734591 | Long-QT syndrome-related sodium channel mutations probed by the dynamic action potential clamp technique. |
| Q26823298 | Long-QT syndrome: from genetics to management |
| Q38878680 | Long-term flecainide therapy in type 3 long QT syndrome |
| Q52995955 | Magnetocardiographic turbulence analysis in patients with the long QT syndrome. |
| Q37301466 | Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel |
| Q52012232 | Mechanism of discordant T wave alternans in the in vivo heart. |
| Q49306666 | Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors. |
| Q35053991 | Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. |
| Q47230575 | Mechanisms of Drug Binding to Voltage-Gated Sodium Channels |
| Q33150817 | Mechanisms of genetic arrhythmias: from DNA to ECG. |
| Q48931348 | Mechanistic link between lidocaine block and inactivation probed by outer pore mutations in the rat micro1 skeletal muscle sodium channel |
| Q42680525 | Mechanosensitivity of Nav1.5, a voltage-sensitive sodium channel |
| Q42111305 | Membrane permeable local anesthetics modulate Na(V)1.5 mechanosensitivity |
| Q34170990 | Membrane stretch affects gating modes of a skeletal muscle sodium channel |
| Q83314410 | Metabolic pathways for ion homeostasis and persistent Na(+) current |
| Q36811537 | Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology |
| Q58805534 | Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients |
| Q35783131 | Modelling and imaging cardiac repolarization abnormalities |
| Q40633126 | Modulation of Cardiac Sodium Channel Gating by Protein Kinase A Can Be Altered by Disease-linked Mutation |
| Q38997049 | Molecular Pathophysiology of Congenital Long QT Syndrome |
| Q36411875 | Molecular analysis of potential hinge residues in the inactivation gate of brain type IIA Na+ channels |
| Q34175373 | Molecular and cellular mechanisms of cardiac arrhythmias |
| Q24634068 | Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome |
| Q26825973 | Molecular and genetic basis of sudden cardiac death |
| Q37108947 | Molecular aspects of the congenital and acquired Long QT Syndrome: clinical implications |
| Q28207595 | Molecular basis of an inherited epilepsy |
| Q24671796 | Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action |
| Q33146297 | Molecular biology and the prolonged QT syndromes |
| Q34175659 | Molecular biology of sodium channels and their role in cardiac arrhythmias |
| Q33175314 | Molecular biology of the long QT syndrome: impact on management. |
| Q39845135 | Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3 |
| Q34621064 | Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide |
| Q39443518 | Molecular differential expression of voltage-gated sodium channel α and β subunit mRNAs in five different mammalian cell lines. |
| Q34469735 | Molecular genetic basis of sudden cardiac death |
| Q37480777 | Molecular mechanisms of inherited arrhythmias |
| Q33154363 | Mouse models of long QT syndrome |
| Q39215625 | Multiple targets for flecainide action: implications for cardiac arrhythmogenesis |
| Q39038606 | Murine Electrophysiological Models of Cardiac Arrhythmogenesis |
| Q24308735 | Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome |
| Q28264653 | Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine |
| Q33158299 | Mutation-specific risk in two genetic forms of type 3 long QT syndrome |
| Q36031745 | Mutational analysis of SCN5A gene in long QT syndrome |
| Q44620842 | N ‐glycosylation‐dependent block is a novel mechanism for drug‐induced cardiac arrhythmia |
| Q36019333 | Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism |
| Q48462230 | Na(v)1.5 underlies the 'third TTX-R sodium current' in rat small DRG neurons |
| Q27005721 | Na+ channel function, regulation, structure, trafficking and sequestration |
| Q33573637 | Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes |
| Q39452111 | Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome |
| Q43669272 | Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice |
| Q33941556 | Neurological diseases caused by ion-channel mutations |
| Q38042001 | Neurological perspectives on voltage-gated sodium channels. |
| Q24536353 | Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. |
| Q34563998 | Noisy inputs and the induction of on-off switching behavior in a neuronal pacemaker |
| Q56331128 | Nonlinear science — The impact of biology |
| Q43595378 | Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation |
| Q33940611 | Novel SCN5A mutation in amiodarone-responsive multifocal ventricular ectopy-associated cardiomyopathy |
| Q36512004 | Novel deletion mutation in the cardiac sodium channel inactivation gate causes long QT syndrome |
| Q24295202 | Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3 |
| Q44019185 | Novel mutations in domain I of SCN5A cause Brugada syndrome |
| Q43246929 | Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias. |
| Q48045058 | Pathophysiological mechanisms of dominant and recessive KVLQT1 K+ channel mutations found in inherited cardiac arrhythmias |
| Q34395667 | Pathophysiology of ion channel mutations |
| Q37276416 | Pathophysiology of the cardiac late Na current and its potential as a drug target |
| Q37706952 | Persistent human cardiac Na+ currents in stably transfected mammalian cells: Robust expression and distinct open-channel selectivity among Class 1 antiarrhythmics |
| Q38203726 | Personalized medicine to treat arrhythmias |
| Q28082968 | Perspective: a dynamics-based classification of ventricular arrhythmias |
| Q36455413 | Perturbation of sodium channel structure by an inherited Long QT Syndrome mutation. |
| Q36082956 | Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation |
| Q36339192 | Pharmacogenetics and cardiac ion channels |
| Q33145998 | Pharmacogenetics of cardiac K(+) channels |
| Q33159820 | Pharmacological and non-pharmacological management of the congenital long QT syndrome: the rationale |
| Q37365724 | Pharmacological targeting of long QT mutant sodium channels |
| Q34482842 | Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs |
| Q35871946 | Polygenic Case of Long QT Syndrome Confirmed through Functional Characterization Informs the Interpretation of Genetic Screening Results |
| Q38667401 | Predicting drug-induced QT prolongation and torsades de pointes |
| Q36782181 | Probing kinetic drug binding mechanism in voltage-gated sodium ion channel: open state versus inactive state blockers |
| Q99237786 | Propranolol Attenuates Late Sodium Current in a Long QT Syndrome Type 3-Human Induced Pluripotent Stem Cell Model |
| Q21129289 | Propranolol blocks cardiac and neuronal voltage-gated sodium channels |
| Q47897228 | Protein kinase C-dependent modulation of Na+ currents increases the excitability of rat neocortical pyramidal neurones |
| Q42230425 | Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action |
| Q39270116 | Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells |
| Q37038494 | Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome |
| Q37910205 | Ranolazine: an antianginal drug with antiarrhythmic properties |
| Q35768561 | Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype |
| Q37193538 | Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling |
| Q40962899 | Recent advances in understanding the molecular mechanisms of the long QT syndrome |
| Q35150971 | Recent progress in congenital long QT syndrome |
| Q42645829 | Reduced voltage dependence of inactivation in the SCN5A sodium channel mutation delF1617. |
| Q57805857 | Regulation and physiological function of Nav1.5 and KCNQ1 channels |
| Q47651784 | Regulation of Cardiac Voltage-Gated Sodium Channel by Kinases: Roles of Protein Kinases A and C. |
| Q26863221 | Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment |
| Q48898610 | Regulation of the cardiac voltage-gated Na+ channel (H1) by the ubiquitin-protein ligase Nedd4. |
| Q43193106 | Restoring repolarization in LQT3. |
| Q84961023 | Role of "non-cardiac" voltage-gated sodium channels in cardiac cells |
| Q53894333 | Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure. |
| Q36822944 | Role of sodium channels in propagation in heart muscle: how subtle genetic alterations result in major arrhythmic disorders |
| Q92259842 | Role of the voltage sensor module in Nav domain IV on fast inactivation in sodium channelopathies: The implication of closed-state inactivation |
| Q28249270 | SCN1A mutations and epilepsy |
| Q30858816 | SCN5A is expressed in human jejunal circular smooth muscle cells |
| Q48549245 | SCN5A mutation associated with cardiac conduction defect and atrial arrhythmias |
| Q28116090 | SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia |
| Q40457885 | SCN5A-linked disease syndromes: complex monogenic disorders of cardiac rhythm. |
| Q49851027 | SCN5A: the greatest HITS collection |
| Q42427786 | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
| Q28587466 | Scn3b knockout mice exhibit abnormal sino-atrial and cardiac conduction properties |
| Q33638480 | Selective gamma-ketoaldehyde scavengers protect Nav1.5 from oxidant-induced inactivation |
| Q37658443 | Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts |
| Q39666218 | Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. |
| Q41732524 | Selectivity and toxicity of antiarrhythmic drugs: molecular interactions with ion channels |
| Q34040527 | Single-channel analysis of inactivation-defective rat skeletal muscle sodium channels containing the F1304Q mutation |
| Q24684695 | Single-channel properties of human NaV1.1 and mechanism of channel dysfunction in SCN1A-associated epilepsy |
| Q28587543 | Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a |
| Q84975790 | Sodium Channelopathies: Do We Really Understand What's Going On? |
| Q33726588 | Sodium channel carboxyl-terminal residue regulates fast inactivation |
| Q24544180 | Sodium channel dysfunction in intractable childhood epilepsy with generalized tonic-clonic seizures |
| Q48567326 | Sodium channel gating: no margin for error |
| Q38568991 | Sodium channel haploinsufficiency and structural change in ventricular arrhythmogenesis |
| Q36474163 | Sodium channel inactivation in heart: a novel role of the carboxy-terminal domain |
| Q36267779 | Sodium channel inactivation: molecular determinants and modulation |
| Q37450777 | Sodium channel mutations and arrhythmias |
| Q36474145 | Sodium channel variants in heart disease: expanding horizons |
| Q37713628 | Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia |
| Q40319677 | State-dependent block of human cardiac hNav1.5 sodium channels by propafenone |
| Q36447208 | State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide |
| Q30866710 | State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents |
| Q35816436 | Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro |
| Q42908541 | Structural analyses of Ca²⁺/CaM interaction with NaV channel C-termini reveal mechanisms of calcium-dependent regulation |
| Q40275976 | Structural effects of an LQT-3 mutation on heart Na+ channel gating |
| Q24302400 | Sudden infant death syndrome-associated mutations in the sodium channel beta subunits |
| Q63322981 | Synthesis and biological studies of flexible brevetoxin/ciguatoxin models with marked conformational preference |
| Q24308697 | Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex |
| Q41139993 | TTX-sensitive and -resistant Na+ currents, and mRNA for the TTX-resistant rH1 channel, are expressed in B104 neuroblastoma cells |
| Q33759435 | Targeting voltage sensors in sodium channels with spider toxins. |
| Q34245293 | The Brugada syndrome: clinical, genetic, cellular, and molecular abnormalities |
| Q36597505 | The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome |
| Q58011050 | The Long QT Syndrome |
| Q36412518 | The Na+ channel inactivation gate is a molecular complex: a novel role of the COOH-terminal domain. |
| Q46367175 | The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3. |
| Q37345048 | The arrhythmogenic consequences of increasing late INa in the cardiomyocyte |
| Q37028768 | The cardiac persistent sodium current: an appealing therapeutic target? |
| Q35033696 | The common African American polymorphism SCN5A-S1103Y interacts with mutation SCN5A-R680H to increase late Na current |
| Q51788865 | The complexity of genotype-phenotype relations associated with loss-of-function sodium channel mutations and the role of in silico studies. |
| Q34644992 | The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology |
| Q33163638 | The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. |
| Q37770572 | The genetic and clinical features of cardiac channelopathies. |
| Q35800619 | The genetic basis for inherited forms of sinoatrial dysfunction and atrioventricular node dysfunction |
| Q28262724 | The genetic basis of long QT and short QT syndromes: a mutation update |
| Q33833171 | The genetics of cardiac arrhythmias |
| Q33942334 | The genomics of cardiovascular disorders: therapeutic implications |
| Q44714535 | The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity |
| Q26864515 | The late Na+ current--origin and pathophysiological relevance |
| Q58011071 | The long QT syndrome |
| Q80210284 | The long QT syndrome |
| Q40824135 | The long QT syndrome and torsade de pointes |
| Q38091053 | The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy |
| Q33970623 | The long QT syndromes: genetic basis and clinical implications |
| Q33544546 | The molecular and ionic specificity of antiarrhythmic drug actions |
| Q77475359 | The molecular basis of long QT syndrome and prospects for therapy |
| Q83207713 | The molecular interaction between local anesthetic/antiarrhythmic agents and voltage-gated sodium channels |
| Q36846820 | The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome |
| Q36731634 | The promiscuous nature of the cardiac sodium current |
| Q37621582 | The role of genetic testing in paediatric syndromes of sudden death: state of the art and future considerations |
| Q26823149 | The role of late I Na in development of cardiac arrhythmias |
| Q36474182 | The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers |
| Q40524605 | The sialic acid component of the beta1 subunit modulates voltage-gated sodium channel function |
| Q52689608 | The voltage-gated sodium channel EF-hands form an interaction with the III-IV linker that is disturbed by disease-causing mutations. |
| Q40279082 | Theoretical investigation of the neuronal Na+ channel SCN1A: abnormal gating and epilepsy |
| Q70803334 | Third and long (QT) |
| Q27002550 | Towards a Unified Theory of Calmodulin Regulation (Calmodulation) of Voltage-Gated Calcium and Sodium Channels |
| Q33905030 | Unraveling monogenic channelopathies and their implications for complex polygenic disease |
| Q34561430 | Unusual case of severe arrhythmia developed after acute intoxication with tosylchloramide. |
| Q47435102 | Use-Dependent Block of Human Cardiac Sodium Channels by GS967. |
| Q40845713 | Use-dependent block of cardiac late Na(+) current by ranolazine |
| Q37774882 | Using computational modeling to predict arrhythmogenesis and antiarrhythmic therapy |
| Q48921398 | Utility of a simplified lidocaine and potassium infusion in diagnosing long QT syndrome among patients with borderline QTc interval prolongation. |
| Q37364440 | Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes |
| Q33778333 | Voltage-gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells |
| Q36652537 | Voltage-gated sodium channels: action players with many faces |
| Q91964347 | Wanted: Class VI Antiarrhythmic Drug Action; New Start for a Rational Drug Therapy |
| Q42621770 | Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels |
| Q34504394 | hERG potassium channels and cardiac arrhythmia |
Search more.